BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Protagonist Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:27 pm Sale |
2024-09-30 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 2,970,427 4.900% |
-2,793,521 (-48.47%) |
Filing |
| 2024-02-14 09:31 am Purchase |
2023-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 5,763,948 9.990% |
738,048 (+14.68%) |
Filing |
| 2023-03-20 5:04 pm Purchase |
2023-03-10 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 5,025,900 9.600% |
3,775,900 (+302.07%) |
Filing |
| 2023-02-13 6:19 pm Sale |
2022-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 1,250,000 2.500% |
-3,641,945 (-74.45%) |
Filing |
| 2022-02-11 9:03 pm Purchase |
2021-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 4,891,945 9.990% |
616,980 (+14.43%) |
Filing |
| 2021-02-12 9:17 pm Purchase |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 4,274,965 9.990% |
1,942,335 (+83.27%) |
Filing |